Sequestration of Platelets Prior to Bypass Reduces Bleeding After Cardiac Surgery

This study has been terminated.
(Funding expired, low recruitment)
Sponsor:
Information provided by:
Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT00359398
First received: August 1, 2006
Last updated: September 18, 2009
Last verified: September 2009

August 1, 2006
September 18, 2009
August 2006
July 2009   (final data collection date for primary outcome measure)
Incidence of coagulation abnormalities as assessed by thromboelastography and platelet function analyser [ Time Frame: At end of surgery (usually <1 day) ] [ Designated as safety issue: No ]
Incidence of coagulation abnormalities as assessed by thromboelastography and platelet function analyser
Complete list of historical versions of study NCT00359398 on ClinicalTrials.gov Archive Site
  • Volume of blood lost into chest drains during first 24 post-operative hours [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
  • Volume of blood product administered during first 24 post-operative hours [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
  • Length of stay in the intensive care unit (ICU) [ Time Frame: Usually < 30 days ] [ Designated as safety issue: Yes ]
  • ICU mortality [ Time Frame: Usually < 30 days ] [ Designated as safety issue: Yes ]
  • Incidence of surgical re-exploration [ Time Frame: Hospital admission (usually < 30 days) ] [ Designated as safety issue: Yes ]
  • Incidence of surgical re-exploration
  • Volume of blood lost into chest drains during first 24 post-operative hours
  • Volume of blood product administered during first 24 post-operative hours
  • Length of stay on the intensive care unit
  • ICU mortality
Not Provided
Not Provided
 
Sequestration of Platelets Prior to Bypass Reduces Bleeding After Cardiac Surgery
Post-operative Administration of Platelet Rich Plasma Sequestered Prior to Cardiopulmonary Bypass Reduces the Coagulopathy Associated With Complex Cardiac Surgery

Excessive bleeding is common after cardiac surgery. This may result in patients receiving a blood transfusion or suffering the life-threatening complication of cardiac tamponade. Tamponade is when excessive bleeding compresses the heart and prevents it from pumping properly. A major reason for the bleeding is the damage done to platelets by the cardiopulmonary bypass (CPB) machine. Often patients receive platelets and plasma from blood donors to try to reduce the bleeding post-operatively. The investigators plan to take platelets and plasma from patients before they are damaged. They would then return these 'undamaged' sequestered platelets to the patients after the bypass machine is no longer needed. Therefore, the investigators' primary question is whether platelet sequestration would reduce the bleeding problems that occur following cardiac surgery. They will evaluate bleeding problems using thromboelastography, which provides a comprehensive assessment of both how blood clots form and their strength. If sequestration reduces bleeding problems following cardiac surgery then it may reduce the chance of patients receiving blood products from donors. Although donated blood is thoroughly tested, its use does expose patients to the risk of transfusion errors, blood borne infections and reactions. Avoiding its use would be very desirable.

Hypothesis:

Patients undergoing repeat median sternotomy or requiring prolonged cardiopulmonary bypass (CPB) often develop a coagulopathy at the end of surgery. We propose sequestering plasma and platelets from these patients prior to CPB and thus prior to the dilution and platelet damage that occurs with CPB. We hypothesise that if these plasma and platelets are stored properly during CPB, and administered at the end of the operation, they will reduce any coagulopathy and the associated bleeding.

Study population:

Patients undergoing repeat median sternotomy, mitral valve repair, double valve operations, aortic surgery, or combined valve and coronary artery surgery.

Exclusion criteria will include those with anaemia, thrombocytopenia, unstable angina, anti-platelet therapy within the previous seven days, known or symptomatic cerebrovascular disease, known disorders of haemostasis, aprotinin sensitivity and pregnancy.

Intervention:

Patients will be randomised by a closed envelope technique to receive platelet/plasma sequestration or not. Patients randomised to undergo sequestration will have 14 mL/Kg blood taken. The blood will be separated into red cells and platelets/plasma. Anaemia would be prevented by returning the processed red blood cells to the patient. We will store platelets at 20-24°C/room temperature on a platelet rocker according to guidelines from the National Blood Service.

Assessment of coagulation:

Patients' coagulation status will be evaluated before and after surgery. Four methods will be employed to comprehensively assess the coagulation system: platelet counts and conventional clotting studies; heparin levels; thromboelastography; and platelet function analyser.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
  • Cardiac Surgical Procedures
  • Cardiopulmonary Bypass
  • Blood Platelet Disorders
  • Blood Coagulation Disorders
Procedure: Platelet rich plasma sequestration
Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
Other Name: Haemonetics cell salavage system
  • Experimental: Platelet sequestration
    Sequestration of platelet rich plasma before cardiopulmonary bypass
    Intervention: Procedure: Platelet rich plasma sequestration
  • No Intervention: Standard care
    No platelet rich plasma sequestration undertaken before cardiopulmonary bypass (usual practice)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
30
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

Adult patients undergoing cardiac surgery that involves:

  • Repeat median sternotomy
  • Mitral valve repair
  • Double valve operations
  • Combined valve and coronary surgery
  • Anticipated prolonged cardiopulmonary bypass

Exclusion Criteria:

  • Pre-operative anaemia
  • Pre-operative thrombocytopenia
  • Unstable angina
  • Anti-platelet therapy (e.g. aspirin, clopidogrel) within the previous 7 days
  • Known or symptomatic cerebrovascular disease
  • Known disorders of haemostasis
  • Aprotinin sensitivity
  • Pregnancy.
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00359398
2006IC003B
Yes
Wendy Butcher, Head of Research and Development, Royal Brompton Hospital
Royal Brompton & Harefield NHS Foundation Trust
Not Provided
Principal Investigator: Simon J Finney, MBChB, PhD Royal Brompton & Harefield NHS Foundation Trust
Principal Investigator: Andrea Kelleher, MBBS Royal Brompton & Harefield NHS Foundation Trust
Principal Investigator: Judith Hall Royal Brompton & Harefield NHS Foundation Trust
Principal Investigator: Simon Davidson, PhD Royal Brompton & Harefield NHS Foundation Trust
Royal Brompton & Harefield NHS Foundation Trust
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP